»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
1eC1Cyw
S Rs~p
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 "4c
?hH:C
lv_|ws
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© (pBOv:6
1.Antigen presenting cell£¨APC£© b #U
nE
2.Activation induced cell death£¨AICD£© )clSW
3.Chemokine iB[>uW
4.Major histocompatibility complex£¨MHC£© 3$Ew55
5.immunotolerance ^06f\7A
)ndcBwQc"
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© 0HUSN_3F
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ /\L|F?+@
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà %Gp%l
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ _@CY_`a
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ S pxkB!
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã 6e,|HV
Ju3-ZFUS4
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© rj[2XIO
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ :fI|>I
~
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ OU;R;=/]
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ V{17iRflf
y=i_:d0M
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ \F]X!#&+
c"BFkw
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 u"IYAyzL
~m^.&mv3/
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩
sg"J00
1.Antigenic determinant }ge~Nu>w
2.IgSF WAPN,WuW
3.MBL;¾¶ ;AV[bjRE\
4.chemokine N9LBji;nH
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ X|+ o4R?
6.TCR-CD3¸´ºÏÎï ,KvF:xqA
7.FADD£¨Fas-associated protein with death domain£© IC&x
L9
8.AIDS 5/j7 C>
9.Tumor rejection antigen `N$:QWJ
10.AICD &phers
f49pIcAq
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ [{.e1s<EK
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© >]N}3J}47g
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ &YQ
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ yZup4#>8
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì r[xj,eIb
`"CIy_m
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ 2NS(;tBB0
d-e6hI4b
JCoDe.
רҵ¿Î ÃâÒßѧ ~R7F[R
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê hdky:2^3
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell 6&8 ([J
5. Fc¦Å receptor 6. Cytokine Vfkm{*t)
¶þ¡¢ ÎÊ´ðÌâ v{%x,K56
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 }Ruj h4*
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ /.1c<!
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ ~JjL411pG
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 N ] KS\
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠtHF-OarUO
,(d\! T/]'
l-;u*JA
8MIn~
"B18|#v
}yQ&[Mt
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ !*2cK>`
`SDpOqfIrP
Ul"9zTH
רҵ¿Î ÃâÒßѧ iuxI$
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê Swugt"`nN
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen :H9\nU1
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin ckn0I
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test xBba&A]=
9. Hybridoma technic 10.Mitogen <( "M;C3y
11.Dentritic cell 12.Immunoproliferation @Z0?1+k
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ 6"3-8orj
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ QaAA@l
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠe6?iQ0
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£
-PfBL8
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ 91I6-7# Xt
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ \!O3]k,r
xIt' o(jQH
!H)$_d \uj
/
-J
qq
Vjx?bKe
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ \[\4= !v
fL xGaOT
"Wz8f
רҵ¿Î ÃâÒßѧ + 6noQYe
Ò»¡¢ Ãû´Ê½âÊÍ mS$9D{
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï Zr(4Q9fDo
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà $C
gl$A
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ <QuIX A
¶þ¡¢ ÎÊ´ðÌâ K20,aWBq;3
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ MQc<AfW3/
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ MZ2/ks
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ #!0=I
s^
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ x5w5xw
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ 2Kkm-#p7
^4 MJ
bIXudE[8zq
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ (HEi;
cp:U@Nh
(
{4n
רҵ¿Î ÃâÒßѧ (U{,D1?
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê bI-uF8"
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR vh$I
f0
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA -lY,lC>{
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM 2jVvK"C
¶þ¡¢ ÎÊ´ðÌâ a1>Tz
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ [+F6C
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ .9u0WP95
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ bMA0#e2
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ &wX568o
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ S.zY0
?NVX# t'
+=`*`eP:U
yMz dM&a!*
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ A-e
RL`
uv&4
A,h
8 7z]qE
רҵ¿Î ÃâÒßѧ N!//m?}
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê ,rNv}
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule J'E?Z0
5. Autogous mixed lymphoyte reaction KY%LqcC
¶þ¡¢ ÎÊ´ðÌâ
|})v,
oB
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ YO9ofT
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ 6zp]SPY
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷ÓᣠkxLWk%V
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ >|pN4FS
5K,=S
j a4zLf(<
;LC?3.
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ yf2P6b\
g_JSgH!4
4$y P_3
רҵ¿Î ÃâÒßѧ I_Omv{&u
[NK&s:wMk
HPXJRQBE
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê -br): }f
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance ^x2@KMKXZ
5. Delayed type hypersensitivity XE8%t=V!c$
¶þ¡¢ ÎÊ´ðÌâ ]wUH*\(y
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ XG E.*aI
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ txiX1o!/L
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ UZ1Au;(|
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠ; Kh!OBZFo
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷Óᣠ+q%b'!&Q
B dP+>Ij
Wjli(sT#-
? ph>:M
D,()e^o
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ p/HGI)'
FzAzAl5
VNs3.
רҵ¿Î ÃâÒßѧ buDz]ec
b
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê QabLMq@n`
1. hypersensitivity 2. cluster of differentiation DUwms"I,%
3. adhesion molecules 4. supper antigen 5. split tolerance p*U!94Pb
¶þ¡¢ ÎÊ´ðÌâ 2$'bOo
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ n7|,b-
<
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ F_0@Sh"
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ +p$lVnAt
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ B}J0d
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ /iL*)
hrGX65>
h@TP=
S%e)
br}
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ !Sl_qL
רҵ¿Î ÃâÒßѧ -e>Z!0
Ò»¡¢ Ãû´Ê½âÊÍ av_ +M;G
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å X|aD>CT
5. GVHR LQR^lD+_=
¶þ¡¢ ÎÊ´ðÌâ /&9R*xNST#
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷Óᣠ7GCxd#DJ
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌØµãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ cI&XsnY
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌØµã¡£
qt6@]Y
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ QP<.~^ao
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ y.-Kqa~
qFl|q0\ A
X3~`~J
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ $R+rB;=a!
Hv2[=e lc
*!j!o%MB
רҵ¿Î ÃâÒßѧ T^{=c
x9x9
Ò»¡¢Ãû´Ê½âÊÍ `xZ,*G7(*
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å Q3Y(K\
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ +D
O<M1uE
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ C XNYWx
11. »ìºÏÁܰÍϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ uKj(=Rqq
Èý¡¢ ÎÊ´ðÌâ HK
Ir?
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ 'Hs*
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ RS@[ +! :t
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà |>1#)cONW
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ &C)97E
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ Ps<k 2
@%YbptT}
)."dqq^ q
BR_fOIDc
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ (;H% r &
t*dq*(3"c
6L)7Q0Z
רҵ¿Î ÃâÒßѧ U3{4GmrT
Ò»¡¢Ãû´Ê½âÊÍ E25w^x2
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó Xbrc_V\_
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁܰÍϸ°ûµÄ±íÃæ±êÖ¾ Se37-
Èý¡¢ ÎÊ´ðÌâ TB= _r(:l+
1. ¼òÊöTÁܰÍϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ )vpYVr-
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ L"NfOST3'R
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ =''b `T$
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ ,el[A`b
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ C\vOxBAB
P,xJVo\
Le{.B@2-"
z-:>[Sn
2?v }w<Ydl
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ YpRhl(|
Ò»¡¢Ãû´Ê½âÊÍ nR w f;K
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï r .
(}
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó ?;.=
o?e9
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡
ls7P$qq
¶þ¡¢ ÎÊ´ðÌâ 1L!jI2~x}
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ {"2CI^!/U.
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ "dE[X`
}=
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£
qm
enj
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ Q#.E-\=^
5hDy62PRr
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ %tZrP$DQ
Ò»¡¢ Ãû´Ê½âÊÍ pn){v
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ #};Zgixo$
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ xU6dRjYhH9
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© K5\l
(BB
10¡¢ ÒõÐÔÑ¡Ôñ a2kAZCQ
¶þ¡¢ ÎÊ´ðÌâ vy2"B ch
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿
rKd|s7l
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ i\gt
@
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 KrHKM 3<
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ K[
S>EITr
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. Q&_#R(3j;
a/3'!} &e
T!HAE#xC
&GvSgdttv
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ LnN:;h
"a33m:]J
jp@X,HES
רҵ¿Î ÃâÒßѧ -S&9"=v
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ *M0O&" ~j
1. Cytokines 2. adhesion molecules 3. graft versus host reaction TXS`ey
4. immunologic tolerance 5. Opsonization 0uPcEpIA
Èý¡¢ ÎÊ´ðÌâ aGsO~ODc
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷Óᣠe7\gd\
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ UvB\kIH
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ 4mEJu
4. ÃâÒßϵͳɱÉ˰Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ FeQo,a
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ pY&dw4V
Br&&#
rg]b$tL~
;:ZD<'+N
<S6?L[_
C=U4z|Ym
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ LmJ _$?o
m(kv:5<>
=?wDQ:
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ )`\Q/TMl5
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ Us2> 5 :\
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê >uQjygjj
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ wN/v-^2
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û b E40^e
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö 0]]OE+9<c
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð o8%o68py
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖÆ±¸ÔÀí¡£ H!6&'=c {k
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ 0JR)-*
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃæ¿¹ÔºÍ±íÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© V$Oj@vI
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ -;qK_
x
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ d/$e#8
:6EX-Xyj
.Zs.O/
'xaEG,P
DZb0'+jQ
UCFFF%
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ aYHs35
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ )qFqf<:yc
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ 6Iz!_
O<Ay`p5
Ò»¡¢ Ãû´Ê½âÊÍ L5 Ai
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß Ju;^^
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò
4
Sdj#w
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô ?@Tsd@s~r
¶þ¡¢ÎÊ´ðÌâ rfSEL
57'
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ %P#|
}
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì \X]I: 0^j
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì tO"AeZe%|
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ HyYJ"54
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ ('d,Sh
n>SK2`